Bruce Hendry

Company: Travere Therapeutics

Job title: Executive Director

Seminars:

Detailing the First Non-Immunosuppressive Therapy Approved for IgAN 9:00 am

Uncovering its unique mechanism of action of blocking both endothelin and angiotensin receptors Highlighting the study design and targeted population Discussing the potential for its use in combination therapyRead more

day: Conference Day One